208 related articles for article (PubMed ID: 15288291)
1. European collaboration in trials of new agents for children with cancer.
Ablett S; Doz F; Morland B; Vassal G; ;
Eur J Cancer; 2004 Aug; 40(12):1886-92. PubMed ID: 15288291
[TBL] [Abstract][Full Text] [Related]
2. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.
Smith MA; Anderson BD
Eur J Cancer; 2004 Aug; 40(12):1893-5. PubMed ID: 15288292
[TBL] [Abstract][Full Text] [Related]
3. Can Canada sustain paediatric phase I trials? A national survey of cancer relapse in children.
Lau L; Baruchel S;
Can J Clin Pharmacol; 2005; 12(3):e222-8. PubMed ID: 16278494
[TBL] [Abstract][Full Text] [Related]
4. Developing new agents for the treatment of childhood cancer.
Kurmasheva R; Morton C; Houghton PJ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
[TBL] [Abstract][Full Text] [Related]
5. [Present strategy for new drug development in the USA].
Shimada Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():315-24. PubMed ID: 7986110
[TBL] [Abstract][Full Text] [Related]
6. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
7. From laboratory to Phase I/II cancer trials with recombinant biotherapeutics.
Tolner B; Smith L; Hillyer T; Bhatia J; Beckett P; Robson L; Sharma SK; Griffin N; Vervecken W; Contreras R; Pedley RB; Begent RH; Chester KA
Eur J Cancer; 2007 Nov; 43(17):2515-22. PubMed ID: 17933516
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
9. European Commission considers revisions to clinical trials directive.
Mason E
J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
[No Abstract] [Full Text] [Related]
10. [Recent proposals for early stage clinical trials of cancer].
Ohashi Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106
[TBL] [Abstract][Full Text] [Related]
11. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium.
Zwaan CM; Kearns P; Caron H; Verschuur A; Riccardi R; Boos J; Doz F; Geoerger B; Morland B; Vassal G;
Cancer Treat Rev; 2010 Jun; 36(4):328-34. PubMed ID: 20231057
[TBL] [Abstract][Full Text] [Related]
12. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
13. Early phase clinical trials in pediatric hematology and oncology.
Corbacioglu S
Klin Padiatr; 2012 Apr; 224(3):197-200. PubMed ID: 22511313
[TBL] [Abstract][Full Text] [Related]
14. [Principle and practice of clinical phase III studies].
Morant R
Onkologie; 2008; 31 Suppl 2():53-7. PubMed ID: 18487870
[TBL] [Abstract][Full Text] [Related]
15. Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.
Anderson BD; Adamson PC; Weiner SL; McCabe MS; Smith MA
J Clin Oncol; 2004 Dec; 22(23):4846-50. PubMed ID: 15570088
[TBL] [Abstract][Full Text] [Related]
16. The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future.
Marshall JL; Gehan EA
Clin Adv Hematol Oncol; 2007 Mar; 5(3):167-72. PubMed ID: 17519876
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience.
Morgenstern DA; Hargrave D; Marshall LV; Gatz SA; Barone G; Crowe T; Pritchard-Jones K; Zacharoulis S; Lancaster DL; Vaidya SJ; Chisholm JC; Pearson AD; Moreno L
J Pediatr Hematol Oncol; 2014 Apr; 36(3):218-23. PubMed ID: 24322496
[TBL] [Abstract][Full Text] [Related]
18. KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration.
Expert Rev Anticancer Ther; 2002 Oct; 2(5):481. PubMed ID: 12382509
[No Abstract] [Full Text] [Related]
19. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
20. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
Andoh M; Fujiwara Y; Shimada Y
Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
